Sun, Aug 18 12:48am

Compare AMGN

Amgen Inc [AMGN]
$204.02 4.71 (2.36%)

AMGN Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 122.35 Billion
AMGN Description

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).

Visit Website

AMGN Earnings

EPS 3.59 P/E Ratio 15.15
Previous Earnings Tue, Apr 30, 2019
Latest Earnings Tue, Jul 30, 2019 (19 days ago) +15.87%

AMGN Dividend

Yield 2.84% / $5.80
Ex-Date Wed, Aug 14, 2019 (4 days ago)
Pay Date Fri, Sep 6, 2019
History 33 Payments (Quarterly)

AMGN Charts

1 Year
May 31, 2019
Sep 27, 2018

Symbol Price Day % YTD %
AMGN $204.02 2.36% 6.32%

Symbol Surfing

How can we make Symbol Surfing better?

Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.

©2019 Symbol Surfing All Rights Reserved.

Cookies Policy | Terms Of Service | Privacy Policy